Xu SX, Yang F, Ge N, Guo JT, Sun SY. Role of albumin-bilirubin score in non-malignant liver disease. World J Gastroenterol 2024; 30(9): 999-1004 [PMID: PMC10989493 DOI: 10.3748/wjg.v30.i9.999]
Corresponding Author of This Article
Si-Yu Sun, MD, PhD, Professor, Department of Gastroenterology, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sunsy@sj-hospital.org
Research Domain of This Article
Gerontology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 7, 2024; 30(9): 999-1004 Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.999
Role of albumin-bilirubin score in non-malignant liver disease
Shi-Xue Xu, Fan Yang, Nan Ge, Jin-Tao Guo, Si-Yu Sun
Shi-Xue Xu, Fan Yang, Nan Ge, Jin-Tao Guo, Si-Yu Sun, Department of Gastroenterology, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Xu SX, Yang F, Ge N, Guo JT, and Sun SY contributed to this study; Xu SX and Sun SY designed the overall concept and outline of the manuscript; Yang F, Ge N, and Guo JT contributed to the discussion and design of the manuscript; Xu SX and Yang F contributed to the writing and editing of the manuscript, illustrations, and review of the literature.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Si-Yu Sun, MD, PhD, Professor, Department of Gastroenterology, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sunsy@sj-hospital.org
Received: December 14, 2023 Peer-review started: December 14, 2023 First decision: January 4, 2024 Revised: January 12, 2024 Accepted: February 18, 2024 Article in press: February 18, 2024 Published online: March 7, 2024 Processing time: 82 Days and 17.5 Hours
Abstract
The albumin-bilirubin (ALBI) score, which was proposed to assess the prognosis of patients with hepatocellular carcinoma, has gradually been extended to other liver diseases in recent years, including primary biliary cholangitis, liver cirrhosis, hepatitis, liver transplantation, and liver injury. The ALBI score is often compared with classical scores such as the Child-Pugh and model for end-stage liver disease scores or other noninvasive prediction models. It is widely employed because of its immunity to subjective evaluation indicators and ease of obtaining detection indicators. An increasing number of studies have confirmed that it is highly accurate for assessing the prognosis of patients with chronic liver disease; additionally, it has demonstrated good predictive performance for outcomes beyond survival in patients with liver diseases, such as decompensation events. This article presents a review of the application of ALBI scores in various non-malignant liver diseases.
Core Tip: The application of albumin-bilirubin score in liver diseases is not limited to hepatocellular carcinoma. In addition to predicting disease progression, it can also be used to predict survival in other non-malignant liver diseases.
